ArticleJournal of hepatocellular carcinoma2025
Intensity-Modulated Proton Therapy for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis.
Article in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) have poor outcomes and limited treatment options. Clinical data specifically evaluating the effects of intensity-modulated proton therapy (IMPT) for this population remain scarce. We reported the outcomes of patients with HCC with PVTT treated with IMPT. Material and Methods: We retrospectively reviewed the data of 83 patients with nonmetastatic HCC with PVTT treated with IMPT between March 2019 and June 2023. Survival outcomes were analyzed with Kaplan-Meier analysis, and prognostic factors were identified via multivariable Cox regression. Treatment responses were assessed with the modified Response Evaluation Criteria in Solid Tumors. Toxicities, including liver dysfunction and gastrointestinal events, were documented. Results: The median overall survival (OS) was 32.4 months, with 1- and 2-year OS rates of 82.6% and 61.0%, respectively. The 2-year local control rate was 88.8%, and the objective response rate was 91.5%. Complete response after IMPT was independently associated with improved OS and liver control, whereas an albumin-bilirubin (ALBI) grade of 2 predicted a greater risk of liver dysfunction. Grade 3 gastrointestinal toxicities occurred in 4.8% of patients, and radiation-induced liver disease occurred in 9.3%. IMPT facilitated curative-intent surgery in 8.4% of patients after treatment. Conclusion: IMPT offers excellent local control and a favorable safety profile in patients with HCC and PVTT, with the potential to downstage tumors for curative interventions. These findings, though limited by the retrospective design and heterogeneity of systemic therapies, support the integration of IMPT into multidisciplinary treatment strategies and highlight the need for prospective studies to clarify its role alongside systemic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.